PRODIGY

NCT01515748 📎

Regimen

Experimental
neoadjuvant DOS x3 + surgery + adjuvant S-1 (CSC)
Control
surgery + adjuvant S-1 (SC)

Population

Korean patients with cT2-3N+ or T4 locally advanced gastric cancer

Key finding

Adjusted PFS HR 0.70 (95% CI 0.52-0.95, P=0.023) for neoadj DOS+surgery+adj S-1 vs surgery+adj S-1; 3-yr PFS 66.3% vs 60.2%

Source: PMID 34133211

Timeline

    Guideline citations

    • NCCN GASTRIC (p.45)
    • CSCO GASTRIC 2025 (p.66)⚠️ OCR source